+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

T

Actively Recruiting

Researchers are evaluating intensity-modulated post-operative radiation therapy I-PORT combined with standard chemotherapy or immunotherapy versus standard therapy alone for patients with non-small cell lung cancer NSCLC who have remaining lymph node cancer after surgery. This phase II trial aims to determine if I-PORT improves disease-free survival and assesses its impact on severe late cardiopulmonary side effects compared to standard care. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy or immunotherapy alone, while the other undergoes I-PORT daily Monday through Friday over 5 to 6 weeks, starting 4 to 12 weeks after surgery, followed by standard therapy. Throughout the study, patients have CT andor MRI scans, FDG-PET scans, and blood samples collected. Treatment continues until disease progression or unacceptable side effects occur. After completing treatment, participants are followed every 3 months for 2 years and then every 6 months for an additional 3 years. The study measures disease-free survival up to 5 years, overall survival at 2 and 5 years, rates of local and distant cancer control, and patient-reported symptoms related to heart and lung health. Safety is closely monitored, focusing on acute and late side effects affecting the heart and lungs.

Age: 18Years +All GendersPhase 2
125 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations
R

Actively Recruiting

Researchers are evaluating how well sentinel lymph node SLN biopsy surgery works compared to standard elective neck dissection END for treating early-stage oral cavity squamous cell carcinoma cT1-2N0. This phase IIIII trial aims to see if SLN biopsy leads to better patient-reported neck and shoulder function and quality of life six months after surgery, while also assessing if disease-free survival with SLN biopsy is not worse than with END. The study also examines patterns of cancer recurrence, overall survival, and treatment toxicity between the two surgical approaches. Participants are randomly assigned to one of two groups. In Group I, patients receive an imaging agent injection followed by planar imaging and SPECTCT scans over 1-2 hours, then undergo SLN biopsy surgery. Group II patients undergo the standard elective neck dissection surgery. Both groups have imaging assessments including FDG PETCT, CT, andor chest x-rays at screening and during follow-up. The trial also collects patient-reported outcomes using questionnaires and measures surgical factors like hospital stay length and operative morbidity. During the study, participants complete quality of life and function questionnaires before surgery, and at 3 weeks, 3, 6, and 12 months after surgery. Follow-up visits occur 3 weeks post-surgery, every 3 months for the first year, every 4 months in the second year, every 6 months in the third year, and yearly thereafter. Researchers monitor disease-free survival, overall survival, and other outcomes for up to 11 years. Biospecimens are also collected for future studies.

Age: 18Years +All GendersPhase 2Phase 3
107 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
R

Actively Recruiting

Researchers are evaluating radiation therapy with or without the chemotherapy drug cisplatin in patients with stage III-IVA squamous cell carcinoma of the head and neck who have had surgery to remove their tumor. This phase II trial aims to understand if adding cisplatin to radiation therapy improves disease-free survival, especially in relation to different types of p53 gene mutations, which might affect treatment outcomes. The study also looks at side effects and explores genetic changes that could influence new treatments. Participants are randomly assigned to one of two groups one group receives intensity-modulated radiation therapy IMRT alone once daily, five days a week for six weeks, while the other group receives the same radiation schedule combined with weekly intravenous cisplatin over 1 to 2 hours for six weeks. After completing treatment without disease progression or unacceptable side effects, patients enter a follow-up period lasting up to 10 years. During the study, participants undergo assessments including surgical tumor tissue analysis for p53 mutations, imaging tests to exclude distant disease, and regular health evaluations. After treatment, patients are monitored every six months for three years and then annually for seven more years to track disease recurrence or new tumors. The main outcome measured is disease-free survival, focusing on the time from randomization to recurrence, second primary tumor, or death.

Age: 18Years +All GendersPhase 2
679 locations
S

Actively Recruiting

Researchers are evaluating whether 6 months of HER2-targeted therapy is as effective as 12 months for treating early-stage HER2-positive breast cancer in patients who have no remaining invasive cancer after preoperative chemotherapy with trastuzumab. The study aims to compare recurrence-free survival and quality of life between shorter and longer treatment durations. Secondary goals include assessing serious side effects, overall survival, local cancer recurrence, and patient-reported symptoms. Participants are randomly assigned to either 6 months or 12 months of HER2-targeted therapy using trastuzumab and possibly pertuzumab, given intravenously or subcutaneously every 21 days. Treatment continues up to 9 or 17 cycles unless disease progresses or side effects are unacceptable. During the trial, participants undergo heart function tests ECHO or MUGA, imaging such as mammography, ultrasound, or MRI, and may provide blood and tissue samples for research. After treatment, participants are followed every 6 months for 5 years or until cancer recurrence, then annually up to 10 years. Researchers monitor recurrence-free survival and quality of life using validated questionnaires. Safety is closely tracked through adverse event reporting, and long-term outcomes including overall survival and brain metastasis occurrence are assessed to understand treatment impact.

Age: 18Years +All GendersPhase 3
702 locations
C

Actively Recruiting

Researchers are evaluating radiation therapy options for men with high-risk prostate cancer in this phase III trial. The study compares a shorter course of stereotactic body radiation therapy SBRT, which delivers five high-dose treatments over two weeks, to the usual longer radiation therapy given over 4 to 9 weeks. The goal is to see if the shorter treatment is as effective in preventing cancer from returning as the standard therapy. Participants are randomly assigned to one of two groups the first group receives SBRT with five treatments over two weeks, and the second group undergoes external beam radiation therapy EBRT with 20 to 45 treatments over 4 to 9 weeks. Both groups may have bone scans, CT, MRI, or PETCT scans during screening and on study, and they may optionally provide blood and urine samples. This trial includes follow-up visits every six months for five years to monitor outcomes. During the study, participants will have various assessments including imaging and questionnaires to evaluate urinary, bowel, sexual function, fatigue, quality of life, and treatment burden. Researchers will track metastasis-free survival, failure-free survival, overall survival, adverse events, and patient-reported outcomes up to 15 years. The study aims to provide detailed information about the effectiveness and impact of the shorter radiation therapy compared to the usual treatment.

Age: 18Years +MALEPhase 3
436 locations

1-10 of 15

1